|
Arix Bioscience PLC (ARIX)
Result of Annual General Meeting 2022
07-Jun-2022 / 16:44 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Arix Bioscience plc
Result of Annual General Meeting 2022
LONDON, 7 June 2022: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), announces that at its Annual General Meeting (the "Meeting") duly convened and held today, all resolutions as set out on the notice of meeting were duly passed by way of a poll. Resolutions 1 to 11 were passed as ordinary resolutions. Resolutions 12 to 15 were passed as special resolutions.
Full details of the poll results are set out below and will also be available on the Company's website.
|
No
|
RESOLUTION
|
VOTES FOR
|
%
|
VOTES AGAINST
|
%
|
TOTAL VOTES
|
% of ISC VOTED
|
VOTES WITHHELD
|
|
1
|
To receive the Directors' Report and the accounts of the Company for the year ended 31 December 2021
|
63,669,622
|
99.99%
|
5,609
|
0.01%
|
63,675,231
|
49.29%
|
10,853
|
|
2
|
To approve the Directors' Remuneration Policy
|
63,589,770
|
99.90%
|
65,188
|
0.10%
|
63,654,958
|
49.28%
|
31,126
|
|
3
|
To approve the Directors' Remuneration Report
|
60,232,861
|
94.62%
|
3,422,747
|
5.38%
|
63,655,608
|
49.28%
|
30,476
|
|
4
|
To re-elect Peregrine Moncreiffe as a Director
|
60,068,424
|
94.35%
|
3,599,164
|
5.65%
|
63,667,588
|
49.29%
|
18,496
|
|
5
|
To re-elect Maureen O'Connell as a Director
|
59,600,160
|
93.61%
|
4,068,028
|
6.39%
|
63,668,188
|
49.29%
|
17,896
|
|
6
|
To re-elect Isaac Kohlberg as a Director
|
63,450,417
|
99.66%
|
217,771
|
0.34%
|
63,668,188
|
49.29%
|
17,896
|
|
7
|
To re-elect Robert Lyne as a Director
|
63,451,455
|
99.66%
|
216,733
|
0.34%
|
63,668,188
|
49.29%
|
17,896
|
|
8
|
To elect Sir Michael Bunbury as a Director
|
60,231,844
|
94.60%
|
3,436,344
|
5.40%
|
63,668,188
|
49.29%
|
17,896
|
|
9
|
To appoint BDO LLP as auditors of the Company
|
63,659,891
|
99.98%
|
12,947
|
0.02%
|
63,672,838
|
49.29%
|
13,246
|
|
10
|
To authorise the Audit and Risk Committee of the Company to fix the auditor's remuneration
|
63,667,766
|
99.99%
|
4,772
|
0.01%
|
63,672,538
|
49.29%
|
13,546
|
|
11
|
To authorise the Directors to allot shares
|
63,632,590
|
99.94%
|
40,130
|
0.06%
|
63,672,720
|
49.29%
|
13,364
|
|
12
|
Authority to disapply statutory pre‐ emption rights
|
58,648,467
|
92.11%
|
5,021,253
|
7.89%
|
63,669,720
|
49.29%
|
16,364
|
|
13
|
Additional authority to disapply statutory pre‐ emption rights
|
58,653,953
|
92.12%
|
5,015,767
|
7.88%
|
63,669,720
|
49.29%
|
16,364
|
|
14
|
To authorise the Company to purchase its own shares
|
63,648,630
|
99.96%
|
22,560
|
0.04%
|
63,671,190
|
49.29%
|
14,894
|
|
15
|
Authority to call a general meeting, other than an annual general meeting, on not less than 14 clear days' notice
|
63,666,745
|
99.99%
|
8,786
|
0.01%
|
63,675,531
|
49.29%
|
10,553
|
In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism, which can be accessed at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The full text of the resolutions considered at the AGM are contained in the Notice of AGM, published on 12 May 2022, which is available on Arix investor relations website.
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
+44 (0)20 7290 1050
ir@arixbioscience.com
Powerscourt Group
Sarah MacLeod, Ibrahim Khalil, Nick Johnson
+44 (0)20 7250 1446
arix@powerscourt-group.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
|
